Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

Nils Kroeger, Wanling Xie, Jae Lyn Lee, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Sandy Srinivas, Ulka N. Vaishamayan, Sun Young Rha, Sumanta K. Pal, Takeshi Yuasa, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, Min Han Tan, Scott A. North, Brian I. Rini, Toni K. Choueiri, Daniel Y.C. Heng

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.

Original languageEnglish
Pages (from-to)2999-3006
Number of pages8
JournalCancer
Volume119
Issue number16
DOIs
Publication statusPublished - 2013 May 28

Fingerprint

Databases
Treatment Failure
Renal Cell Carcinoma
Survival
Therapeutics
Clear-cell metastatic renal cell carcinoma
Vascular Endothelial Growth Factor A
Neutrophils

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kroeger, Nils ; Xie, Wanling ; Lee, Jae Lyn ; Bjarnason, Georg A. ; Knox, Jennifer J. ; MacKenzie, Mary J. ; Wood, Lori ; Srinivas, Sandy ; Vaishamayan, Ulka N. ; Rha, Sun Young ; Pal, Sumanta K. ; Yuasa, Takeshi ; Donskov, Frede ; Agarwal, Neeraj ; Kollmannsberger, Christian K. ; Tan, Min Han ; North, Scott A. ; Rini, Brian I. ; Choueiri, Toni K. ; Heng, Daniel Y.C. / Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents : Characterization of survival outcome and application of the International mRCC Database Consortium criteria. In: Cancer. 2013 ; Vol. 119, No. 16. pp. 2999-3006.
@article{68979451b3cb49e39a0d78381ba2d71a,
title = "Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria",
abstract = "BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95{\%} CI, 1.19-1.67; P <.0001) and 1.54 (95{\%} CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.",
author = "Nils Kroeger and Wanling Xie and Lee, {Jae Lyn} and Bjarnason, {Georg A.} and Knox, {Jennifer J.} and MacKenzie, {Mary J.} and Lori Wood and Sandy Srinivas and Vaishamayan, {Ulka N.} and Rha, {Sun Young} and Pal, {Sumanta K.} and Takeshi Yuasa and Frede Donskov and Neeraj Agarwal and Kollmannsberger, {Christian K.} and Tan, {Min Han} and North, {Scott A.} and Rini, {Brian I.} and Choueiri, {Toni K.} and Heng, {Daniel Y.C.}",
year = "2013",
month = "5",
day = "28",
doi = "10.1002/cncr.28151",
language = "English",
volume = "119",
pages = "2999--3006",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

Kroeger, N, Xie, W, Lee, JL, Bjarnason, GA, Knox, JJ, MacKenzie, MJ, Wood, L, Srinivas, S, Vaishamayan, UN, Rha, SY, Pal, SK, Yuasa, T, Donskov, F, Agarwal, N, Kollmannsberger, CK, Tan, MH, North, SA, Rini, BI, Choueiri, TK & Heng, DYC 2013, 'Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria', Cancer, vol. 119, no. 16, pp. 2999-3006. https://doi.org/10.1002/cncr.28151

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents : Characterization of survival outcome and application of the International mRCC Database Consortium criteria. / Kroeger, Nils; Xie, Wanling; Lee, Jae Lyn; Bjarnason, Georg A.; Knox, Jennifer J.; MacKenzie, Mary J.; Wood, Lori; Srinivas, Sandy; Vaishamayan, Ulka N.; Rha, Sun Young; Pal, Sumanta K.; Yuasa, Takeshi; Donskov, Frede; Agarwal, Neeraj; Kollmannsberger, Christian K.; Tan, Min Han; North, Scott A.; Rini, Brian I.; Choueiri, Toni K.; Heng, Daniel Y.C.

In: Cancer, Vol. 119, No. 16, 28.05.2013, p. 2999-3006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents

T2 - Characterization of survival outcome and application of the International mRCC Database Consortium criteria

AU - Kroeger, Nils

AU - Xie, Wanling

AU - Lee, Jae Lyn

AU - Bjarnason, Georg A.

AU - Knox, Jennifer J.

AU - MacKenzie, Mary J.

AU - Wood, Lori

AU - Srinivas, Sandy

AU - Vaishamayan, Ulka N.

AU - Rha, Sun Young

AU - Pal, Sumanta K.

AU - Yuasa, Takeshi

AU - Donskov, Frede

AU - Agarwal, Neeraj

AU - Kollmannsberger, Christian K.

AU - Tan, Min Han

AU - North, Scott A.

AU - Rini, Brian I.

AU - Choueiri, Toni K.

AU - Heng, Daniel Y.C.

PY - 2013/5/28

Y1 - 2013/5/28

N2 - BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.

AB - BACKGROUND This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P <.0001) and more often presented with low hemoglobin (P =.014) and elevated neutrophils (P =.0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P <.0001) and TTF (4.2 vs 7.8 months; P <.0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P <.0001) and 1.54 (95% CI, 1.33-1.79; P <.0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P <.0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P <.0001). CONCLUSIONS Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84881480218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881480218&partnerID=8YFLogxK

U2 - 10.1002/cncr.28151

DO - 10.1002/cncr.28151

M3 - Article

C2 - 23696129

AN - SCOPUS:84881480218

VL - 119

SP - 2999

EP - 3006

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -